SCHEMBL9926091

SCHEMBL9926091

COc1ccc(N2CCN(C(=O)[C@@H]3CN(S(=O)(=O)c4cc(Br)c(Br)s4)C[C@H]3c3ccccc3)CC2)cc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.52
POLB P06746 3/20 0.52
LMNA P02545 2/20 0.52
SMN1; SMN2 Q16637 9/20 0.48
SIGMAR1 Q99720 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
MEN1 O00255 1/20 0.42
APEX1 P27695 1/20 0.42
RECQL P46063 1/20 0.42
KMT2A Q03164 1/20 0.42
CTDSP1 Q9GZU7 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
MAPK1 P28482 2/20 0.42
ALDH1A1 P00352 3/20 0.41
GAA P10253 3/20 0.41
HTT P42858 1/20 0.41
DRD2 P14416 1/20 0.40
DRD4 P21917 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5264524 1.00 MAPT (0.52) MAPTPOLBLMNASMN1; SMN2SIGMAR1
SCHEMBL13987571 0.92 MAPT (0.62) MAPTPOLBLMNASMN1; SMN2SIGMAR1
SCHEMBL5264662 0.88 MAPT (0.50) MAPTPOLBLMNASMN1; SMN2SIGMAR1
SCHEMBL9926066 0.88 MAPT (0.50) MAPTPOLBLMNASMN1; SMN2SIGMAR1
SCHEMBL5268393 0.87 SMN1; SMN2 (0.50) MAPTPOLBLMNASMN1; SMN2SIGMAR1
SCHEMBL9926050 0.87 MC4R (0.51) MAPTPOLBLMNASMN1; SMN2MEN1
SCHEMBL5266541 0.87 MC4R (0.51) MAPTPOLBLMNASMN1; SMN2MEN1
SCHEMBL9926069 0.87 SMN1; SMN2 (0.50) MAPTPOLBLMNASMN1; SMN2SIGMAR1
SCHEMBL9926127 0.85 SMN1; SMN2 (0.49) MAPTPOLBLMNASMN1; SMN2SIGMAR1
SCHEMBL9926051 0.85 SMN1; SMN2 (0.67) MAPTSMN1; SMN2SIGMAR1L3MBTL1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836180-B1 SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS SANOFI SA (FR) 2012-06-13 EP disclosed
US-7468369-B2 Sulfonyl pyrrolidines, method for producing the same and their use as drugs SANOFI-AVENTIS (FR) 2008-12-23 US disclosed
US-7468369-B2 Sulfonyl pyrrolidines, method for producing the same and their use as drugs SANOFI-AVENTIS (FR) 2008-12-23 US disclosed
US-20080045540-A1 SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-02-21 US disclosed
US-20080045540-A1 SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045540-A1 SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS SLC5A1, SLC5A2, KCNJ1 MAPT 4225/4885POLB 4401/4885LMNA 3961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.